H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) shares dropped 49.5% during trading on Monday . The company traded as low as $2.02 and last traded at $2.02. Approximately 400 shares traded hands during trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Trading Down 49.5 %
The stock has a 50-day moving average of $2.02 and a 200 day moving average of $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Articles
- Five stocks we like better than H-CYTE
- How to Use the MarketBeat Stock Screener
- Rocket Lab is the Right Stock for the Right Time
- What Are Growth Stocks and Investing in Them
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- The Role Economic Reports Play in a Successful Investment Strategy
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
